Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
J Vet Cardiol ; 17 Suppl 1: S190-201, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26776577

ABSTRACT

Feline heartworm disease presents a unique diagnostic, therapeutic, and preventive challenge for veterinarians. Due to the elusive clinical nature and peculiar physiopathology of heartworm infection in cats, a multistep diagnostic process is mandatory. Clinical signs may be absent or atypical. At the present time there is no single ante mortem diagnostic test that can reach a high level of sensitivity for feline heartworm infection. The most efficient approach for the diagnosis of feline heartworm disease is based upon a synergic association of several tests: thoracic radiography and serum antibody tests for rising index of suspicion, and echocardiography and serum antigen tests for confirming the infection. Other tests should be considered of secondary importance, even if they can help to support the diagnosis. Treatment of feline heartworm disease is typically based on clinical signs, as adulticidal therapy is associated with a high rate of complications and cats frequently self-cure. Chemoprophylaxis, knowledge of the biology of the parasite, and a high index of suspicion seem to be the most important tools for combating feline heartworm disease.


Subject(s)
Cat Diseases/parasitology , Dirofilariasis/diagnosis , Filaricides/therapeutic use , Animals , Cat Diseases/diagnosis , Cats , Dirofilariasis/drug therapy
2.
Rev Med Suisse ; 8(358): 1956, 1958-60, 2012 Oct 17.
Article in French | MEDLINE | ID: mdl-23198648

ABSTRACT

Large-volume paracentesis is the procedure of choice for refractory or symptomatic ascitis. However, there is a risk for Post-paracentesis Circulatory Dysfunction (PCD) leading to hyponatremia, renal failure, or worsening portal hypertension. PCD may be effectively prevented by volume expanders, essentially albumin, administered during and after the procedure, but the data regarding the impact of this treatment on mortality are still limited. For this reason, there is a debate about the true clinical benefit of preventing PCD, explaining some variations among published guidelines. The efficacy of molecules other than albumin is still under study but none has shown real superiority so far.


Subject(s)
Albumins/therapeutic use , Ascites/therapy , Cardiovascular Diseases/prevention & control , Liver Cirrhosis/complications , Paracentesis/adverse effects , Ascites/etiology , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...